After defending her Ph.D. in the field of bioorganic chemistry in 2005, Séverine Denoyelle joined the Faculty of Pharmacy of Montpellier as a postdoctoral fellow. As part of the European project “Antimal”, her research work consisted in the development of new oral drugs for the treatment of Malaria. From 2007 to 2009, Séverine carried out a two-year postdoctoral training at Harvard Medical School, Boston, MA, where she focused on the design and the synthesis of small molecules, namely diarylureas and oxindoles, for cancer therapy. In 2009, Séverine became associate professor in medicinal chemistry at the Faculty of Pharmacy of Montpellier where she joined the Institute of Biomolecules Max Mousseron (IBMM). Her main research project focuses on the development of ligands targeting the Ghrelin receptor (GHSR), a GPCR that mediates growth hormone secretion, food intake, and reward-seeking behaviors. Because of its possible implication in several physiological disorders such as obesity and drugs/alcohol addictions, GHSR represents a major target for the development of therapeutic small molecules. More recently, Séverine has also been interested in the development of new methodologies to access heterocyclic scaffolds such as [1,2,4]triazoles, diazepinones and triazolo-ketopiperazines in order to find new potential lead compounds for therapeutic applications.